富智康(02038.HK)向印度附屬公司注資1億美元
富智康(02038.HK)公布,於本月4日,公司於新加坡註冊成立之間接全資附屬公司Wonderful
Stars將會向其於印度註冊成立之直接附屬公司Rising Stars注資總金額近1億美元作多種用途,包括用於業務擴展及作為額外營運資金。
Rising Stars於緊隨該注資後之已發行股本總額將增至238.09億印度盧比,其中99.97%由Wonderful Stars持有,餘下0.03%由公司於新加坡註冊成立之另一家間接全資附屬公司Aptech Electronics Pte. Ltd.持有。
Rising Stars之主要業務為生產手機、通訊工具及電子產品連同相關軟件專利及程式。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.